HOME >> BIOLOGY >> NEWS
Collaborative Cross to provide powerful resource for mouse model researchers worldwide

OAK RIDGE, Tenn., Sept. 22, 2005 -- A thousand new strains of mice being bred at Oak Ridge National Laboratory as part of an international effort will provide researchers with a powerful resource for studying human disease.

The project, dubbed the Collaborative Cross, has officially begun with a $1.25 million grant over five years from the Ellison Medical Foundation. When completed in about seven years, researchers worldwide will be able to fully exploit the genetic power of the mouse. Each of the estimated 1,000 strains derived from the carefully selected original eight breeds represents a resource that can be used repeatedly to accumulate data.

"Ultimately, this effort will allow us to do a much better job of modeling human populations and diseases because we will have 1,000 lines of mice that carry the kinds of genetic diversity representative of people," said Dabney Johnson, a genetics researcher in ORNL's Life Sciences Division. Johnson headed a team that wrote the proposal to the Ellison Medical Foundation.

At the heart of the project is the new $14 million Laboratory for Comparative Functional Genomics at the Department of Energy's ORNL. The pathogen-free 36,000-square-foot facility completed in 2004 boasts accommodations for 80,000 mice, cryogenic storage and other state-of-the-art features. It is at this designated DOE user facility that the breeding of the eight strains taken from around the world will be performed to initiate up to 1,500 strains of mice. Of those, researchers expect about 1,000 strains to be viable as inbreeding proceeds.

Without DOE's stewardship of the new mouse facility, the project would not be possible, said Johnson, who noted that DOE is contributing not only the space within the facility but also the technical capabilities that will allow the work to be performed.

The project, which will occupy about half of the new ORNL mouse house's capacity, is a perfect fit for ORNL, according to Johnson.
'"/>

Contact: Ron Walli
wallira@ornl.gov
865-576-0226
DOE/Oak Ridge National Laboratory
22-Sep-2005


Page: 1 2 3

Related biology news :

1. Collaborative study successfully applies neutrons to study hydrogen transfer in biological systems
2. A Cross-Disciplinary Look at Scientific Truth: Whats the Law to Do?
3. Crossing the Valley of Death: Moving science into practice and policy
4. Stem Cells: Saving Lives or Crossing Lines?
5. New study suggests Concord grape juice may provide protection against breast cancer
6. Female gender provides an advantage in renal diseases
7. Forecasting system provides flood warnings to vulnerable residents of Bangladesh
8. Discovery of new protein could provide new understanding of male fertility
9. Einstein researchers prototype vaccine could provide improved protection against tuberculosis
10. Genomics study provides insight into the evolution of unique human traits
11. Expert to provide update after worst tomato virus hits California

Post Your Comments:
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, reminds investors and ... Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, ... 2015. The three-day conference is organized into ... speaking in is themed Global Fraud: Where is the ...
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
(Date:5/27/2015)... , May 27, 2015  Two years after its ... hackers and citizen scientists, Oakland -based ... campaign promoting its mission to democratize science through a ... Photo ... Based out of the new ...
(Date:5/27/2015)... 2015 ­ Caris Life Sciences®, a leading ... medicine, today announced it has appointed the Levine Cancer ... excellence site in the Caris Centers of Excellence for ... Institute is one of the largest cancer care providers ... cancer patients annually. Derek Raghavan , M.D., Ph.D., ...
(Date:5/26/2015)... , Kalifornien und HILDEN, Deutschland, May 26, ... Clinical Insight ®   ... und die Erstellung dazugehöriger Berichte; Vorstellung auf ... QIAGEN N.V. (NASDAQ: QGEN ... die Markteinführung von QIAGEN Clinical Insight ® ...
(Date:5/26/2015)... -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ), ... modernized traditional Chinese medicine (mTCM), branded generics and active ... of Shareholders for fiscal year ended June 30, 2014 ... office located in Chengdu, China ... in Chengdu, China ) on May ...
Breaking Biology Technology:East Bay's Counter Culture Labs Seeks to Open Doors of Science to Public 2East Bay's Counter Culture Labs Seeks to Open Doors of Science to Public 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 2Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 4QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 2QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 3QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 4QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 5QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 6TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements 2TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements 3
Cached News: